期刊
HEART FAILURE REVIEWS
卷 19, 期 3, 页码 369-381出版社
SPRINGER
DOI: 10.1007/s10741-013-9396-5
关键词
Heart failure; Biomarkers; Personalized medicine; Soluble ST2; Galectin-3; MicroRNAs
资金
- Dutch Heart Foundation [2006T37]
- European Commission [FP7-242209-BIOSTAT-CHF]
Biomarkers play an important role in heart failure. They provide us information about the mechanisms involved in specific types of heart failure and can identify patients at higher risk. Although the majority of biomarker studies in heart failure focus on their prognostic value, the clinical applicability of prognostication in heart failure needs to be established. However, biomarkers can be used for many other purposes. For example, they can help us with the diagnosis of heart failure, and they can be used to select our therapy, leading to personalized tailored therapy. Finally, when biomarkers are causally involved in the disease process, they can even become targets for therapy. The present paper reviews the established and potential value of the novel heart failure biomarkers, mid-regional atrial natriuretic peptide, soluble ST2, growth differentiation factor 15, galectin-3, renal tubular damage markers, and microRNAs. Their potential clinical value will be discussed and compared with the reference markers, the natriuretic peptides.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据